Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06933329 · ClinicalTrials.gov registry record · Phase 2
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by BicycleTx Limited.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
- 20
- Study locations
NCT06933329: Recruiting Phase 2 study of Non-Small Cell Lung Cancer, sponsored by BicycleTx Limited.
NCT06933329 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by BicycleTx Limited. The registered enrollment target is 73 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06933329, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by BicycleTx Limited.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior line of systemic therapy in the advanced/metastatic setting (see inclusion criteria below). The study will comprise of 2 cohorts: Cohort A (non-squamous NSCLC) and Cohort B (squamous NSCLC).
Conditions Studied
Interventions
- DRUG Zelenectide pevedotin
Study Locations (20)
Other
- Institut Bergonie - Bordeaux
- Centre Hospitalier Intercommunal de Créteil - Créteil
- Centre Leon Berard - Lyon
- Institut Curie - Paris
- Les Hôpitaux Universitaires de Strasbourg - Strasbourg
- Hopital Foch - Suresnes
- Complejo Hospitalario Universitario A Coruña - A Coruña
- Hospital Clinic de Barcelona - Barcelona
- Hospital Universitario 12 de Octubre - Madrid
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Texas
- Texas Oncology - Central South - Austin
- Texas Oncology - DFW - Dallas
Alaska
- Alaska Oncology and Hematology, LLC - Anchorage
California
- University of California, Davis Comprehensive Cancer Center - Sacramento
Montana
- St. Vincent Regional Hospital - Cancer Centers of Montana - Billings
New York
- Clinical Research Alliance, Inc - Westbury
Ohio
- Oncology Hematology Care Clinical Trials, LLC - Fairfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2025-07-18 |
| Est. Completion | 2029-02-28 |
| Phase | Phase 2 |
What NCT06933329 shows while recruiting
NCT06933329 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Zelenectide pevedotin is the first listed.
NCT06933329 names 20 study sites across 10 states, led by Other, Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT06933329 about?
NCT06933329 is a clinical study titled "Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer". This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior line of systemic therapy in th...
What is the current status of trial NCT06933329?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2025-07-18. Estimated completion is 2029-02-28.
What conditions does trial NCT06933329 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06933329?
The interventions under investigation include: Zelenectide pevedotin (DRUG).
Who is sponsoring clinical trial NCT06933329?
This trial is sponsored by BicycleTx Limited, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06933329 being conducted?
This trial has 20 study locations across Alaska, California, Massachusetts, Montana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06933329's enrollment target sits among peer trials
73 282nd of 454 higher than 172 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06247345 · 73 participants · Phase 1
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI